ROSENZWEIG RICHARD C
Known title: SVP and General CounselCIK: 0001206725
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ANGO Announces Q1 Fiscal 2027 Results Date. AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.
Transaction History
| XRAY | ▲ Buy | Grant | 766 | $0 | 10/10/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 595 | $0 | 7/11/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 628 | $0 | 4/11/2025 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 1,440 | $22K | 3/4/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 33,771 | $0 | 3/3/2025 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 1,452 | $23K | 3/3/2025 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 4,956 | $79K | 3/3/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 383 | $0 | 1/10/2025 | View on chart |
| XRAY | ▲ Buy | Grant | 267 | $0 | 10/11/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 288 | $0 | 7/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 215 | $0 | 4/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 11,644 | $0 | 3/4/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 1,356 | $45K | 3/1/2024 | View on chart |
| XRAY | ▼ Sell | Tax Withholding | 4,736 | $158K | 3/1/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 194 | $0 | 1/12/2024 | View on chart |
| XRAY | ▲ Buy | Grant | 201 | $0 | 10/13/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 171 | $0 | 7/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 174 | $0 | 4/14/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 10,003 | $0 | 3/3/2023 | View on chart |
| XRAY | ▲ Buy | Grant | 38,720 | $0 | 3/3/2023 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 1,137 | $15K | 2/1/2023 | View on chart |
| ANGO | ▲ Buy | Grant | 3,963 | $0 | 7/20/2022 | View on chart |
| ANGO | ▼ Sell | Tax Withholding | 1,194 | $25K | 2/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage
XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.
XRAY: Earnings, Target Cut, Expansion, Medicare Coverage. XRAY reported its Q2 earnings, prompting analysts to review the company’s outlook. Piper Sandler lowered its target to $12, citing the reset strategy after a new Midwest dental partnership. Meanwhile, the Wellspect unit announced Medicare reimbursement for its Surity urinary portfolio, expanding the company’s product reach. These developments add new layers to XRAY’s growth narrative.